Strategic board

 

Alexis COLLOMB, PhD, board chairman

Alexis Collomb is the chairman of Peptinov’s strategic board.

Alexis held several positions in investment banks in New York and London, prior to becoming Professor of Finance in Cnam (Conservatoire National des Arts et Métiers) University in Paris, his current position.

With his keen interest and expertise in innovation funding, Alexis brings to Peptinov over ten years of experience as a business angel in the biotech field. He holds a Masters degree and a PhD from Stanford University and is a member of the scientific board of IHEIE (Higher Learning Institute for Innovation & Entrepreneurship)/Mines ParisTech.


 

André ABRIC, former CEO Kyowa Kirin Pharma France

André Abric brings to Peptinov more than 40 years of experience in healthcare. He started his career in Sandoz, with different positions, from medical delegate to business unit director and finally member of the executive board.

The main focus of his career was the successful creation (ex nihilo mostly) of pharmaceutical laboratories in France, such as Schwarz Pharma, Mundipharma, Basilea, Archimedes, the latter eventually merging with ProStrakan to become Kyowa Kirin Pharma France. Through this merger, this company, dedicated to oncology supportive care treatment, entered the rare diseases market. 

André’s vast experience spans from privately-held to listed companies in both classic pharmas and biotechs, notably in global and market access strategy, and will be a great asset for Peptinov.


 

Jean-Charles GROLLEMUND, CEO of IRCEM group

Jean-Charles Grollemund represents IRCEM in Peptinov’s strategic board.

Mr. Grollemund joined IRCEM in 2000 and has been the CEO of the group since 2007. Mr. Grollemund has a vast experience in the insurance field, in which he has worked during his whole career. Under his leadership, IRCEM launched a microloan service (IRCEM plus) to promote job creation. He was involved in the creation of www.ircem.com, a portal for home and family services, as well as in various initiatives to facilitate public access to information in the social security field.


Jean-François ZAGURY, MD, PhD, Founder

Prof. Zagury graduated from Ecole Normale Superieure (Paris) and he then obtained his medical degree and his PhD in Immunology from Pierre and Marie Curie University. He has authored more than 100 publications in peer-reviewed international scientific journals and is inventor of 18 patents. He is currently chair professor of the Department of Bioinformatics at CNAM University, Paris. His laboratory was recently given an A+ evaluation by the French National Research Agency in all criteria, positioning it in the top 5% of French laboratories. He has the full support of his university to work on Peptinov’s project. He was co-founder and CEO of Neovacs (ALNEV, EN Paris) from 1992 to 1998 and its CSO from 2001 to 2003. He founded Peptinov in 2009 to develop his works on anti-cytokine active immunization.


 

René AZOULAI, CEO

René Azoulai is Peptinov’s CEO. He’s a graduate engineer from Ecole Polytechnique & Telecom ParisTech. He has more than 20 years of experience managing business units and innovative strategies in the fields of IT services and in the air transport industry, at senior executive level and on a worldwide scale. He has also been in charge of M&As and of an international joint venture operation. René has been a significant investor in Peptinov since 2009, as well as a member of its board. Peptinov will greatly benefit from his managerial, strategic and business development experience during its current expansion phase, including on an international basis.